Familial Cancer

, Volume 11, Issue 2, pp 157–165

Hereditary medullary thyroid carcinoma: the management dilemma

  • Ping Zhou
  • Jian Liu
  • Shao-Wen Cheng
  • Bing Wang
  • Rong Yang
  • Ling Peng
Review

DOI: 10.1007/s10689-011-9501-7

Cite this article as:
Zhou, P., Liu, J., Cheng, S. et al. Familial Cancer (2012) 11: 157. doi:10.1007/s10689-011-9501-7

Abstract

Hereditary medullary thyroid carcinoma (hereditary MTC) is a rare malignancy, accounting for 25–30% of all MTC. It occurs as part of multiple endocrine neoplasia type 2 (MEN 2). Autosomal dominant gain-of-function mutations in the RET proto-oncogene is the cause of the disease, in which the common mutations are codons 609, 611, 618, 620, 630, 634 and 918. In recent years, the spectrum of RET gene mutations has changed. The classical mutations reduced, whereas the less aggressive mutations increased. Hereditary MTC is a time-dependent disease. Stages of the disorder at diagnosis can significantly influence survival rates. Based on the genotype–phenotype, RET mutations have been classified into four risk levels by American Thyroid Association (ATA) at 2009. The classification system guides the hereditary MTC management, including risk assessment, biochemical screenings and surgical intervention. Though the application of genetic testing and codon-specific phenotypes in hereditary MTC diagnosis is effective with high accuracy, there are some difficulties in implementing RET gene testing as a routine for MTC diagnosis. And most of carriers with RET mutations did not undergo thyroidectomy at the age recommended by the ATA guidelines. The aim of the study is to review the hereditary MTC and discuss the management dilemma.

Keywords

Hereditary medullary thyroid carcinomaRET proto-oncogeneMutationManagementProphylactic thyroidectomy

Abbreviations

RET

Rearranged during transfection

Hereditary MTC

Hereditary medullary thyroid carcinoma

MEN 2

Multiple endocrine neoplasia type 2

ATA

American Thyroid Association

MTC

Medullary thyroid carcinoma

CCH

C-cell hyperplasia

Pheo

Pheochromocytoma

HPT

Hyperparathyroidism

FMTC

Familial MTC

VUS

Variant of unknown significance

HSCR

Hirschsprung disease

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Ping Zhou
    • 1
  • Jian Liu
    • 4
  • Shao-Wen Cheng
    • 2
  • Bing Wang
    • 1
  • Rong Yang
    • 1
  • Ling Peng
    • 3
  1. 1.Department of Surgical Oncology, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Trauma Center, The Affiliated Hospital of Hainan Medical CollegeHaikouChina
  3. 3.Department of Medical Oncology, The First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  4. 4.Department of Surgical OncologyHangzhou Hospital of Traditional Chinese MedicineHangzhouChina